Use of olaparib in BRCA mutation-positive ovarian cancer
CPD Previous     Next

Use of olaparib in BRCA mutation-positive ovarian cancer

Tracie Miles Lead gynaecology oncology nurse specialist, Royal United Hospitals Bath NHS Foundation Trust, Bath
Lynn Holmes Gynaecological oncology clinical nurse specialist, Castle Hill Hospital, Cottingham, East Yorkshire

Nurses should understand the role and purpose of the new generation of therapies available for patients with cancer. One such drug is the poly (ADP-ribose) polymerase inhibitor olaparib (Lynparza™▼). As it becomes available, it will be important for nurses to understand how it works, how to anticipate any side effects and how to manage these effectively. This article describes the importance of BRCA gene mutations in women with ovarian cancer and introduces olaparib, a targeted agent for use in these women in accordance with its label indication.

Cancer Nursing Practice. 14, 5, 29-36. doi: 10.7748/cnp.14.5.29.e1148


Peer review

This article has been subject to double-blind review and checked using antiplagiarism software. For related articles visit our online archive and search using the keywords

Conflict of interest


Received: 03 October 2014

Accepted: 02 December 2014

Want to read more?

Subscribe for unlimited access

Try 1 month’s access for just £1 and get:

Your subscription package includes:
  • Full access to the website and the online archive
  • Bi-monthly digital edition
  • RCNi Portfolio and interactive CPD quizzes
  • RCNi Learning with 200+ evidence-based modules
  • 10 articles a month from any other RCNi journal
Already subscribed? Log in

Alternatively, you can purchase access to this article for the next seven days. Buy now